
Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

Sygnature Discovery Ltd acquires leading Canadian CRO
The purchase of NuChem Sciences for an undisclosed sum is the third in a series of acquisitions in sixteen months as part of Sygnature's global...

Carbios raises €141m to boost enzymatic PET recycling
Carbios has announced a capital increase of €141m in cash with preferential subscription rights through the issue of 5,558,695 new shares at a...

Retinopathy: Golgi and Breye join forces
The two companies announced their collaboration, which aims to find treatment options for both early-stage diabetic retinopathy (DR) and dry-AMD...

Promising viral gene therapy for genetic kidney disease
UK resesearchers have engineered an adeno-associated virus vector to treat the heriditary steroid-resistant nephrotic syndrome in children, which is...

Seed money for unique topical hair growth inducer
Good news for all those with genetic hormonal hair loss (androgenic alopecia and Alopecia areata): according to the patent specification, an...